Aurinia Pharmaceuticals Inc (STU:IKAP)
€ 9.252 -0.386 (-4%) Market Cap: 1.32 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 3.73 GF Score: 84/100

Q4 2018 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Mar 19, 2019 / 08:30PM GMT
Release Date Price: €5.62 (+2.18%)
Operator

Greetings, and welcome to the Aurinia Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to Dr. Glenn Schulman. Thank you. Please begin.

Glenn Schulman

Thanks, Royanne. Good afternoon, everyone. Welcome to Aurinia's Q4, Year-End 2018 Earnings Call and General Business Update. Joining me on the call today from Aurinia are Dr. Richard Glickman, Chief Executive Officer; Dennis Bourgeault, Chief Financial Officer; Dr. Neil Solomons, Chief Medical Officer; Mr. Michael Martin, Chief Operating Officer.

This afternoon, we issued a press release detailing fourth quarter, year-end 2018 financial results and our corporate update for the year. The press release and associated financial statement package is available on our website at www.auriniapharma.com and informs 40-F and 6-K filed earlier on EDGAR and SEDAR. I'd like to remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot